Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of three different therapeutic approaches

Augusto B. Federici, Federica Stabile, Giancarlo Castaman, Maria Teresa Canciani, Pier Mannuccio Mannucci

Research output: Contribution to journalArticle

Abstract

Patients with monoclonal gammopathies of uncertain significance (MGUS) may develop an acquired bleeding disorder similar to congenital von Willebrand disease, called acquired von Willebrand syndrome (AvWS). In these patients, measures to improve hemostasis are required to prevent or treat bleeding episodes. We diagnosed 10 patients with MGUS and AvWS: 8 had IgGκ (3) or λ (5) MGUS and 2 IgM-κ MGUS. Three therapeutic approaches were compared in them: (1) desmopressin (DDAVP), (2) factor VIII/von Willebrand factor (FVIII/vWF) concentrate, and (3) high-dose (1 g/kg/d for 2 days) intravenous Ig (IVIg). In patients with IgG-MGUS, DDAVP and FVIII/vWF concentrate increased factor VIii and von Willebrand factor in plasma, but only transiently. IVIg determined a more sustained improvement of the laboratory abnormalities and prevented bleeding during surgery (short-term therapy). In addition to the standard 2-day infusion protocol, a long-term IVIg therapy was performed in 2 patients with IgG-MGUS: repeated (every 21 days) single infusions of IVIg did improve laboratory abnormalities and stopped chronic gastrointestinal bleeding. On the other hand, IVIg failed to correct laboratories abnormalities in patients with IgM-MGUS. These comparative data obtained in a relative large and homogeneous group of patients with AvWS and MGUS confirm that DDAVP and FVIII/vWF concentrates improve the bleeding time (BT) and FVIII/vWF measurements only transiently, whereas IVIg provides a sustained treatment of AvWS associated with IgG- MGUS, but not with IgM-MGUS.

Original languageEnglish
Pages (from-to)2707-2711
Number of pages5
JournalBlood
Volume92
Issue number8
Publication statusPublished - Oct 15 1998

Fingerprint

Deamino Arginine Vasopressin
Paraproteinemias
Immunoglobulin G
Immunoglobulin M
Hemorrhage
von Willebrand Factor
Therapeutics
Surgery
Plasmas
factor VIII, von Willebrand factor drug combination
von Willebrand Diseases
Bleeding Time
Hemostasis
Intravenous Infusions

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance : Comparison of three different therapeutic approaches. / Federici, Augusto B.; Stabile, Federica; Castaman, Giancarlo; Canciani, Maria Teresa; Mannucci, Pier Mannuccio.

In: Blood, Vol. 92, No. 8, 15.10.1998, p. 2707-2711.

Research output: Contribution to journalArticle

Federici, Augusto B. ; Stabile, Federica ; Castaman, Giancarlo ; Canciani, Maria Teresa ; Mannucci, Pier Mannuccio. / Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance : Comparison of three different therapeutic approaches. In: Blood. 1998 ; Vol. 92, No. 8. pp. 2707-2711.
@article{6c7f9b348ade4bc998e2d539e8237790,
title = "Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of three different therapeutic approaches",
abstract = "Patients with monoclonal gammopathies of uncertain significance (MGUS) may develop an acquired bleeding disorder similar to congenital von Willebrand disease, called acquired von Willebrand syndrome (AvWS). In these patients, measures to improve hemostasis are required to prevent or treat bleeding episodes. We diagnosed 10 patients with MGUS and AvWS: 8 had IgGκ (3) or λ (5) MGUS and 2 IgM-κ MGUS. Three therapeutic approaches were compared in them: (1) desmopressin (DDAVP), (2) factor VIII/von Willebrand factor (FVIII/vWF) concentrate, and (3) high-dose (1 g/kg/d for 2 days) intravenous Ig (IVIg). In patients with IgG-MGUS, DDAVP and FVIII/vWF concentrate increased factor VIii and von Willebrand factor in plasma, but only transiently. IVIg determined a more sustained improvement of the laboratory abnormalities and prevented bleeding during surgery (short-term therapy). In addition to the standard 2-day infusion protocol, a long-term IVIg therapy was performed in 2 patients with IgG-MGUS: repeated (every 21 days) single infusions of IVIg did improve laboratory abnormalities and stopped chronic gastrointestinal bleeding. On the other hand, IVIg failed to correct laboratories abnormalities in patients with IgM-MGUS. These comparative data obtained in a relative large and homogeneous group of patients with AvWS and MGUS confirm that DDAVP and FVIII/vWF concentrates improve the bleeding time (BT) and FVIII/vWF measurements only transiently, whereas IVIg provides a sustained treatment of AvWS associated with IgG- MGUS, but not with IgM-MGUS.",
author = "Federici, {Augusto B.} and Federica Stabile and Giancarlo Castaman and Canciani, {Maria Teresa} and Mannucci, {Pier Mannuccio}",
year = "1998",
month = "10",
day = "15",
language = "English",
volume = "92",
pages = "2707--2711",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance

T2 - Comparison of three different therapeutic approaches

AU - Federici, Augusto B.

AU - Stabile, Federica

AU - Castaman, Giancarlo

AU - Canciani, Maria Teresa

AU - Mannucci, Pier Mannuccio

PY - 1998/10/15

Y1 - 1998/10/15

N2 - Patients with monoclonal gammopathies of uncertain significance (MGUS) may develop an acquired bleeding disorder similar to congenital von Willebrand disease, called acquired von Willebrand syndrome (AvWS). In these patients, measures to improve hemostasis are required to prevent or treat bleeding episodes. We diagnosed 10 patients with MGUS and AvWS: 8 had IgGκ (3) or λ (5) MGUS and 2 IgM-κ MGUS. Three therapeutic approaches were compared in them: (1) desmopressin (DDAVP), (2) factor VIII/von Willebrand factor (FVIII/vWF) concentrate, and (3) high-dose (1 g/kg/d for 2 days) intravenous Ig (IVIg). In patients with IgG-MGUS, DDAVP and FVIII/vWF concentrate increased factor VIii and von Willebrand factor in plasma, but only transiently. IVIg determined a more sustained improvement of the laboratory abnormalities and prevented bleeding during surgery (short-term therapy). In addition to the standard 2-day infusion protocol, a long-term IVIg therapy was performed in 2 patients with IgG-MGUS: repeated (every 21 days) single infusions of IVIg did improve laboratory abnormalities and stopped chronic gastrointestinal bleeding. On the other hand, IVIg failed to correct laboratories abnormalities in patients with IgM-MGUS. These comparative data obtained in a relative large and homogeneous group of patients with AvWS and MGUS confirm that DDAVP and FVIII/vWF concentrates improve the bleeding time (BT) and FVIII/vWF measurements only transiently, whereas IVIg provides a sustained treatment of AvWS associated with IgG- MGUS, but not with IgM-MGUS.

AB - Patients with monoclonal gammopathies of uncertain significance (MGUS) may develop an acquired bleeding disorder similar to congenital von Willebrand disease, called acquired von Willebrand syndrome (AvWS). In these patients, measures to improve hemostasis are required to prevent or treat bleeding episodes. We diagnosed 10 patients with MGUS and AvWS: 8 had IgGκ (3) or λ (5) MGUS and 2 IgM-κ MGUS. Three therapeutic approaches were compared in them: (1) desmopressin (DDAVP), (2) factor VIII/von Willebrand factor (FVIII/vWF) concentrate, and (3) high-dose (1 g/kg/d for 2 days) intravenous Ig (IVIg). In patients with IgG-MGUS, DDAVP and FVIII/vWF concentrate increased factor VIii and von Willebrand factor in plasma, but only transiently. IVIg determined a more sustained improvement of the laboratory abnormalities and prevented bleeding during surgery (short-term therapy). In addition to the standard 2-day infusion protocol, a long-term IVIg therapy was performed in 2 patients with IgG-MGUS: repeated (every 21 days) single infusions of IVIg did improve laboratory abnormalities and stopped chronic gastrointestinal bleeding. On the other hand, IVIg failed to correct laboratories abnormalities in patients with IgM-MGUS. These comparative data obtained in a relative large and homogeneous group of patients with AvWS and MGUS confirm that DDAVP and FVIII/vWF concentrates improve the bleeding time (BT) and FVIII/vWF measurements only transiently, whereas IVIg provides a sustained treatment of AvWS associated with IgG- MGUS, but not with IgM-MGUS.

UR - http://www.scopus.com/inward/record.url?scp=0032532314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032532314&partnerID=8YFLogxK

M3 - Article

C2 - 9763553

AN - SCOPUS:0032532314

VL - 92

SP - 2707

EP - 2711

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -